الفهرس | Only 14 pages are availabe for public view |
Abstract Ovarian malignancies are considered the fifth to sixth most common cancer in women, causing more annual deaths than any other gynecological malignancies in women worldwide. In the majority of cases, a good prognosis cannot be made at the diagnosis because clinical presentation of the disease occurs at an advanced stage. Ovarian cancers comprise several histologically distinct tumor groups with widely different prognosis, Type I epithelial, germ cell and sex cord-stromal tumors are generally associated with higher survival than type II tumors, so the proportion of these tumors may influence survival estimates for all ovarian cancers combined. The staging system of the International Federation of Gynecology and Obstetrics (F.I.G.O.) is most commonly used for ovarian carcinoma. The stage of disease depends on the extent of the disease at the time of diagnosis. In general, stage I disease is limited to the ovary, stage II is limited to the pelvis, stage III is limited to the abdomen, and stage IV is hematogenous spread or extends beyond the abdomen. As CT. scanners are now readily available in most areas of the world, more studies using CT. scans to evaluate adnexal mass are also more available. In one study, CT. scan seemed to be more accurate than ultrasound (94 vs. 80 %) in differentiating between benign and malignant ovarian tumors. Before surgery, CT. scan characteristics of the adnexal masses were recorded by one investigator. Thus, the CT. scan reading was done without the knowledge of the pathology report. |